A study showed that in mice with whole-body or lineage-specific gene ablation and specific mAbs, Siglec-15 was discovered as an immune suppressive molecule largely operating in the tumor microenvironment (TME) and is non-redundant to the well-known PD-L1/PD-1 pathway. This evidence concerns the gene CD274 and neoplasm.